Status:
COMPLETED
Investigation Of A New Medication (GW642444) In Asthmatic Patients
Lead Sponsor:
GlaxoSmithKline
Conditions:
Asthma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This study will evaluate efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat inhaled doses of GW642444. This will be a multi-centre, double-blind, placebo...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Female subjects must be non-childbearing (i.e., surgically sterilised or post-menopausal).
- Non-smokers for at least 6 months.
- Stable asthma.
- Exclusion criteria:
- Abnormal findings on heart monitoring assessment.
- Lower respiratory tract infection within 4 weeks, upper respiratory tract within 2 weeks of study.
- Currently taking doses of fluticasone propionate over 500mcg/day.
- Unstable asthma medication.
Exclusion
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00354874
Start Date
January 1 2005
End Date
June 1 2005
Last Update
September 15 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Wiesbaden, Hesse, Germany, 65187
2
GSK Investigational Site
Großhansdorf, Schleswig-Holstein, Germany, 22927
3
GSK Investigational Site
Gothenburg, Sweden, SE-413 45